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Abstract
Nuclear hormone receptors play a major role in many important biological processes. Most nuclear hormone receptors are
ubiquitously expressed and regulate processes such as metabolism, circadian function, and development. They function in
these processes to maintain homeostasis through modulation of transcriptional gene networks. In this study we evaluate
the effectiveness of a nuclear hormone receptor gene to modulate retinal degeneration and restore the integrity of the
retina. Currently, there are no effective treatment options for retinal degenerative diseases leading to progressive and
irreversible blindness. In this study we demonstrate that the nuclear hormone receptor gene Nr1d1 (Rev-Erba) rescues Nr2e3-
associated retinal degeneration in the rd7 mouse, which lacks a functional Nr2e3 gene. Mutations in human NR2E3 are
associated with several retinal degenerations including enhanced S cone syndrome and retinitis pigmentosa. The rd7
mouse, lacking Nr2e3, exhibits an increase in S cones and slow, progressive retinal degeneration. A traditional genetic
mapping approach previously identified candidate modifier loci. Here, we demonstrate that in vivo delivery of the candidate
modifier gene, Nr1d1 rescues Nr2e3 associated retinal degeneration. We observed clinical, histological, functional, and
molecular restoration of the rd7 retina. Furthermore, we demonstrate that the mechanism of rescue at the molecular and
functional level is through the re-regulation of key genes within the Nr2e3-directed transcriptional network. Together, these
findings reveal the potency of nuclear receptors as modulators of disease and specifically of NR1D1 as a novel therapeutic
for retinal degenerations.
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Introduction
Genetic heterogeneity (identical mutations with variable clinical
presentation of disease) is a common feature for many Mendelian
disorders [1]. While the underlying mechanisms causing such
variations are case specific, it is clear that environmental factors,
allelic heterogeneity, genetic modifiers, or a combination of these,
can have a profound impact in disease expressivity. Genetic
modifiers are allelic variants distinct from the disease-causing gene
that can alter disease onset, progression or the clinical features for
that particular disease [2]. Since genetic modifiers can result in
either increasing or reducing disease severity, identification of
modifier loci is important for understanding disease pathophysi-
ology, predicting disease progression and developing novel
therapeutic strategies. Modifier loci have been mapped for several
diseases in both human and mouse, including cystic fibrosis,
epilepsy, Huntington’s disease, hearing loss and retinal degener-
ation [3–14]. The availability of extensive genomic tools and
multiple inbred strains of mouse models provide a unique platform
to uncover genetic modifiers that strongly influence phenotypic
variation in human disease [15]. As such, identification of these
modifier genes also provides powerful and novel therapeutics.
While significant disease variability is observed for inherited
retinal degenerative diseases, the underlying causes for such
variations are largely undiscovered [13,16–19]. Mutations in the
nuclear hormone receptor NR2E3, also known as photoreceptor-
specific nuclear receptor (PNR), have been associated with several
retinal diseases including enhanced S-cone syndrome (ESCS),
Goldmann-Favre syndrome and retinitis pigmentosa [20–25].
NR2E3 functions as dual activator and suppressor of gene
expression and, together with transcription factors such as NRL,
CRX and NR1D1, modulates photoreceptor cell fate and
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differentiation [26–31]. NR2E3 is also expressed in mature
photoreceptors where it regulates expression of genes essential
for proper function, such as phototransduction genes [31,32]. The
NR2E3 protein contains four evolutionary conserved domains that
are shared by the nuclear hormone receptor family; namely the
highly variable A/B domain, N terminal DNA binding domain, a
flexible hinge region and the ligand-binding and dimerization
domain in the C terminus [33,34]. More than 30 disease-causing
mutations have been identified in NR2E3, most of which are
located within the DNA binding domain and the ligand-binding
domain [20–25]. While most NR2E3 mutations have a recessive
mode of inheritance, a c.166G.A (p.G56R) mutation in the
NR2E3 gene is associated with autosomal dominant retinitis
pigmentosa [25]. These data show significant phenotypic variation
in patients with NR2E3 associated retinal degeneration. Interest-
ingly, variable clinical presentation is observed even in patients
harboring the same mutation and within the same family,
suggesting that modifier genes modulate disease outcome in these
patients [21,35,36].
The retinal degeneration 7 (rd7) mouse is a model for Nr2e3
associated retinal disease [37,38]. We utilize the Nr2e3rd7/rd7 mouse
model to study the genetic heterogeneity observed in Nr2e3
associated retinal degeneration and to identify genetic modifiers
that contribute to such variation. Mice homozygous for the rd7
mutation develop retinal dysplasia, with whorls and rosettes
apparent at postnatal day 10 (P10) and retinal spots detectable by
fundus examination at eye opening (P14) [37–39]. Similar to
patients with Nr2e3 mutations, rd7 mice exhibit significant increase
of S-cones and progressive degeneration of rod and cone
photoreceptor cells [38]. Our previous studies demonstrated that
the rd7 phenotype is highly variable depending on genetic
background [40]. We observe complete penetrance in the
B6.Cg-Nr2e3rd7/rd7 strain, while suppression occurs in crosses with
the genetically divergent and inbred strains AKR/J, CAST/EiJ
and NOD.NOH-H2nb1, revealing that modifier alleles are
conferring resistance or susceptibility to the Nr2e3rd7/rd7 pheno-
types [40].In this study, we identified the nuclear hormone
receptor Rev-erb alpha, hereafter referred to as Nr1d1, as a genetic
modifier of Nr2e3rd7/rd7. We genetically fine mapped a locus on
chromosome 11 linked to Nr2e3rd7/rd7 suppression in the AKR/J
background and through sequence analysis, identified two strain-
specific variations in the Nr1d1 gene within this locus. Delivery of
the Nr1d1 gene to the retinas of B6.Cg-Nr2e3rd7/rd7 neonates
rescues retinal spotting and retinal dysplasia associated with Nr2e3
loss, confirming that increased Nr1d1 expression is sufficient for
suppressing rd7. Importantly, we show that Nr1d1 delivery results
in re-regulation of key genes within the Nr2e3-directed network
that are essential for proper photoreceptor function. Our findings
uncover NR1D1 as a potential therapeutic target for Nr2e3
associated retinal degeneration that can compensate for Nr2e3 loss
by regulating key molecular pathways associated with disease.
Results
Genetic Fine Mapping of rd7 Modifier Locus on AKR/J
Chromosome 11
Our previous studies revealed that genetic background strongly
influences penetrance of Nr2e3rd7/rd7 phenotypes [37,40]. Specif-
ically, complete suppression of rd7 retinal degeneration was
observed in outcrosses of B6.Cg-Nr2e3rd7/rd7 mice to AKR/J,
CAST/EiJ or NOD.NOH-H2nb1 mice and several modifier loci
that were unique for each strain were identified [40]. Two
suggestive quantitative trait loci (QTL) located on chromosomes 7
and 11 were found to be associated with suppression in the AKR/J
genetic background [40]. To determine if a single modifier gene is
able to ameliorate rd7 associated retinal degeneration, we
generated an incipient congenic strain that harbors the AKR/J
modifier locus on chromosome 11, named Mor7 for modifier of
rd7, by backcrossing F2 progeny from our B6.Cg-Nr2e3
rd7/rd7 6
AKR/J cross to the C57BL/6J inbred strain for six consecutive
generations. Congenic animals carry the modifier loci from AKR/
J on a C57BL/6J genetic background. Approximately 65% of the
B6.Cg-Mor7AKR:Nr2e3rd7/rd7 N6 F2 animals homozygous for the
rd7 mutation did not exhibited the retinal spotting normally
observed in B6.Cg-Nr2e3rd7/rd7 animals, compared to 49% of F2
animals from the initial intercross of B6.Cg-Nr2e3rd7/rd76AKR/
J, suggesting a single modifier gene is sufficient for rd7 suppression.
A genome wide analysis of the congenic F2 animals confirmed that
approximately 95% of the B6.Cg-Mor7AKR:Nr2e3rd7/rd7 genome
harbored C57BL/6J alleles in the N6 generation. Two-thirds of
the B6.Cg-Mor7AKR:Nr2e3rd7/rd7 suppressed mice were heterozy-
gotes across the Mor7 locus, indicating that the AKR/J Mor7 allele
acts as a dominant protective allele. Consistent with our previous
results, the suppressed B6.Cg-Mor7AKR:Nr2e3rd7/rd7 mice harbor-
ing the modifier allele showed restored retinal morphology
(Figures 1A and B) and normal expression of S-cone opsin
(Opn1sw), compared to affected littermates harboring the suscep-
tible allele (Figures 1C and D). Through our fine mapping
analysis, we refined the Mor7 suppressor locus to a 3.3 cM region
in chromosome 11. This region is flanked by markers D11Mit145
and D11Mit360 and contains approximately 200 genes.
Identification of Nr1d1 as a Genetic Modifier of rd7
We utilized a candidate approach to identify the Mor7 gene
responsible for conferring rd7 suppression. Through rigorous in
silico analysis using several publicly available resources (http://
blast.ncbi.nlm.nih.gov, http://www.ensembl.org/index.html,
http://pipeline.lbl.gov/cgi-bin/gateway2, http://www.ncbi.nlm.
nih.gov/geo/), we determined that 95 of the approximately 200
genes that lie within the Mor7 locus are expressed in the retina, 10
of which are transcription factors (Figure 1E). We hypothesized
that the Mor7 modifier gene functions in the same or parallel
pathway as Nr2e3. Three of the identified genes, thyroid hormone
receptor alpha (Thra), retinoid acid receptor alpha (Rara) and rev-
erb alpha (Nr1d1) are, like Nr2e3, members of the nuclear hormone
receptor family. Given that several members of this family have
been described as key regulators of retinal development and
function, Thra, Rara and Nr1d1 were considered strong candidates
for Mor7 and their coding as well as upstream regions were
sequenced to identify allelic variants between C57BL/6J and
AKR/J. While allelic variants were not found in either Thra or
Rara, two single nucleotide polymorphisms (SNPs) were identified
in Nr1d1 at homozygous state (Figure 2).
The SNPs identified in Nr1d1 are located in both the translated
and un-translated regions of the gene. A non-synonymous SNP at
position 1222bp was identified in Nr1d1, resulting in replacement
of the consensus Arginine at position 408 by Glutamine in the
AKR/J NR1D1 protein (Figures 2A and B). This SNP is located
within the highly conserved ligand-binding domain (LBD) of the
NR1D1 nuclear hormone receptor. Specifically, the SNP lies
within the binding domain for the NR1D1 co-repressor N-CoR,
also known as X domain [41]. A second SNP was identified at
position 2105 (Figures 2C and D), within the Nr1d1 promoter
region [42,43]. Specifically, the AKR/J genome harbors a
thymidine at this position whereas a cytosine residue is found in
C57BL/6J. Sequence alignment of the Nr1d1 gene across species
revealed that T is the evolutionary conserved allele at this position
(Figure 2B). As this SNP resides within the putative promoter
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region of Nr1d1, we examined whether Nr1d1 mRNA expression
varies in C57BL/6J versus AKR/J retinas. Quantitative real time
PCR confirmed that Nr1d1 mRNA expression is upregulated by 3
fold in the AKR/J retina, compared to C57BL/6J (P = 0.0024,
Figure 2E). This difference in expression may account for the
suppressed effect observed in AKR/J genetic background. CAST/
EiJ and NOD.NOH-H2nb1 genetic backgrounds also confer
resistance to rd7 associated retinal degeneration; however, genetic
modifiers on these backgrounds mapped to independent chromo-
somal locations. [40]. Quantitative real time PCR shows that while
Nr1d1 mRNA levels are increased in CAST/EiJ and NOD.NOH-
2nb1 wild-type mice compared to B6 (Figure 2F), it is only a slight
increase compared to the differences observed for AKR/J vs B6.
Thus, the increased levels of Nr1d1 in CAST/EiJ and NOD.-
NOH-2nb1 may contribute to rd7 suppression; however, the overall
modification of the rd7 phenotype in those strains is likely due to
the presence of other modifier genes.
Nr1d1 Delivery Restores Retinal Integrity in rd7
NR1D1 regulates many processes such as differentiation,
metabolism, and the circadian rhythm [44]. Recently, our studies
and those of others have demonstrated a role for NR1D1 in the
retina. NR1D1 forms a complex with NR2E3, CRX and NRL,
key transcriptional regulators of retinal development and function
[26]. Importantly, NR1D1 binds the NR2E3 protein directly and
acts synergistically to regulate transcription of photoreceptor-
specific genes [26]. Further, our work identified a number of genes
co-regulated by NR2E3 and NR1D1 in the developing and adult
retina [45]. Thus, Nr1d1 is a strong candidate to modify the effects
of Nr2e3-associated retinal degeneration.
In vivo electroporation was performed to deliver Nr1d1 alleles
from either C57BL/6J or AKR/J into the retina of neonatal rd7
mice and determine whether NR1D1 can modulate rd7 associated
retinal degeneration. The vector used has GFP to detect
expression at the site of delivery. One month after delivery, GFP
expression was present in both the outer nuclear layer, composed
of the cell bodies of rod and cone photoreceptors, and in the inner
nuclear layer of the retina (Figure 3). One month after injection,
animals were examined clinically by indirect ophthalmoscopy for
detection of the characteristic rd7 pan-retinal spotting. While
spotting of the fundus was clearly observable in the eyes
electroporated with the control GFP vector at P30.5, electropo-
ration of GFP.Nr2e3B6 resulted in suppression of the phenotype
(Figures 4C and D). Delivery of either GFP.Nr1d1B6 (B6 allele,
without the LBD SNP) or GFP.Nr1d1AKR/J (AKR/J allele, with the
LBD SNP) also resulted in rescue of the pan-retinal spotting
phenotype (Figures 4E and F). Further, the absence of retinal
spotting correlated with absence of retinal dysplasia in histological
sections (Figures 4G–J). A subset of the electroporated animals
were aged to 4 months and electroretinograms (ERGs) were
performed to examine visual function. Significant improvements
in both scotopic (dark-adapted) and photopic (light-adapted) ERG
response were observed in B6.Cg-Nr2e3rd/7rd7 eyes injected with
GFP.Nr1d1AKR/J, compared to GFP injected eyes (Figures 4K and
L). These studies demonstrate that the dosage of Nr1d1 is sufficient
for rescue of Nr2e3-associated retinal disease irrespective of the
allelic variant in the ligand-binding domain; thus the promoter
SNP is likely the protective allele-mediating rescue of disease.
Nr1d1 delivery results in the molecular rescue of rd7
misregulated genesNR1D1, a regulator of circadian clock
metabolism, also functions as a cofactor of NR2E3 and regulates
expression of a number of genes in the retina [26,45]. We
previously characterized the expression profile of the retinas of rd7
animals and identified 30 genes that are misregulated in Nr2e3
deficient retinas, 24 of which are directly regulated by NR2E3,
NR1D1 or co-regulated by both nuclear hormone receptors [32].
We therefore hypothesized that NR1D1 is able to suppress rd7
associated retinal degeneration through molecular rescue of key
developmental and functional pathways that are misregulated in
the rd7 retina. We specifically focused on evaluating the expression
of Opn1sw (the S-cone specific opsin) and Gnat2 (cone photore-
ceptor specific transducin); key components of the cone photo-
transduction cascade that are significantly upregulated in rd7. We
performed quantitative RT-PCR to assay expression of Opn1sw
and Gnat2 in the retina of rd7 animals 30 days after GFP.Nr1d1AKR/
J delivery. Expression of Opn1sw was 1.5 fold increased in the
Figure 1. rd7 phenotypes are suppressed in N6 B6.Cg-
Mor7AKR:Nr2e3rd7/rd7 mice. (A, B) Hematoxylin and eosin staining of
retinal sections from affected (A) and suppressed (B) F2 B6.Cg-
Mor7AKR:Nr2e3rd7/rd7 P30 animals. Retinal dysplasia was absent in the
suppressed rd7 homozygote animals. (C, D) Labeling of retinal sections
with anti-OPN1SW shows that the S-cone population is restored to a
normal level in suppressed F2 Cg.AKR/J-Nr2e3
rd7/rd7 animals (D),
compared to affected animals (C). (E) Chart showing distribution of
the 95 retinal genes that map to the Mor7 interval. GCL: ganglion cell
layer, INL: inner nuclear layer, ONL: outer nuclear layer, OS: outer
segments, RPE: retinal pigment epithelium.
doi:10.1371/journal.pone.0087942.g001
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retina of untreated rd7 animals (left eye, n= 3) compared to
C57BL/6J, consistent with previous reports (p = 0.004, Figure 5).
GFP.Nr1d1AKR/J delivery to the right eye of the same rd7 animals
resulted in a significant reduction in Opn1sw expression (p = 0.035,
Figure 5). Furthermore, Opn1sw levels in GFP.Nr1d1AKR/J injected
eyes were not significantly different from those present in wild-type
C57BL/6J retinas (p = 0.86), indicating that Nr1d1 delivery rescues
Opn1sw expression to near normal levels. Gnat2 was also
significantly decreased in eyes injected with GFP.Nr1d1AKR/J,
compared to uninjected eyes from the same animals (p = 0.005,
Figure 5). These results suggest that Nr1d1 up-regulation is able to
suppress Nr2e3 associated retinal degeneration by redirecting the
biological networks that modulate photoreceptor development and
function.
Discussion
Photoreceptor biogenesis and homeostasis are directed by key
transcription factors that modulate expression of gene networks in
an ordered fashion both during development and in the mature
retina. Moreover, specific combinations of those transcription
factors to regulatory regions are an important mechanism of
Figure 2. Strain specific alleles and differential expression of Nr1d1. (A) C57BL/6J and AKR/J chromatograms of polymorphisms identified in
the ligand-binding domain of Nr1d1. (B) ClustalW2 sequence alignment of amino acid sequences from C57BL/6J, AKR/J, rat, chimpanzee and human.
Stars indicate identity in all sequences, while dots indicate conserved amino acids. (C) C57BL/6J and AKR/J chromatograms of polymorphisms
identified in the Nr1d1 59UTR region. (D) ClustalW2 sequence alignment across species reveals the consensus is in accordance with AKR/J sequence.
Stars indicate nucleotide conservation in all species. (E) Nr1d1 relative expression in P30.5 AKR/J and C57BL/6J retinas (mean 6 SD of mean, n = 3,
p = 0.0024). (F) Nr1d1 relative expression in P30.5 C57BL/6J, CAST/EiJ and NOD.NOH-H2nb1 retinas (p,0.05).
doi:10.1371/journal.pone.0087942.g002
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transcriptional regulation. Several member of the nuclear receptor
family, such as NR2E3, regulate key transcriptional networks
during these processes. NR1D1 has recently been identified as yet
another nuclear receptor important for proper function of the
mammalian retina. NR1D1 interacts with NR2E3 and functions
in the same transcriptional network [26,32,45]. Our previous
studies show that acute knockdown of NR1D1 by shRNA
targeting in the mouse retina results in retinal degeneration
similar to that observed in rd7 animals [45]. In the present study,
we show that Nr1d1 is a genetic modifier able to ameliorate Nr2e3
associated retinal degeneration and confirm that NR1D1 and
NR2E3 act synergistically to regulate genes involved in retinal
development and function.
Delivery of Nr1d1 alleles from both AKR/J and C57BL/6J
strains was able to rescue disease in rd7. The data presented here
strongly suggests that rescue is mediated by an increase in Nr1d1
gene dosage and is not dependent on the SNP located in the
ligand-binding domain. It is likely that in the AKR/J suppressed
animals the promoter SNP results in increased levels of Nr1d1 that
are sufficient to compensate for Nr2e3 loss. Consistent with this
hypothesis, increased Nr1d1 mRNA expression is observed in the
AKR/J retina compared to C57BL/6J. CAST/EiJ and NOD.-
NOH-H2nb1 have slightly higher Nr1d1 levels compared to
C57BL/6J, but the difference is minimal compared to that of
AKR/J. We previously showed that outcrossing rd7 to CAST/EiJ
and NOD.NOH-H2nb1 leads to suppression of the rd7 phenotype.
Genetic mapping identified unique modifier loci for each strain,
distinct from the Nr1d1-containing loci that significantly associated
with the suppression in ARK/J mice. The minimal increased
levels of Nr1d1 in CAST/EiJ and NOD.NOH-H2nb1 thus likely
does not influence overall modification of the rd7 phenotype in
those strains, however it may provide some resistance [40].
Nr1d1 and Nr2e3 are members of the nuclear hormone receptor
family and as such they have a similar gene structure [46]. Further,
the NR1D1 and NR2E3 proteins interact with each other directly
and regulate common genes/gene networks [26,45]. This inter-
action is important for the regulation of gene promoter activation
complexes including the proteins NRL and CRX. Therefore,
higher Nr1d1 expression may lead to rescue of rd7 by increasing
active complexes that regulate transcription of genes important for
photoreceptor homeostasis and function. This increase in active
complexes may lead to an increased activation of low affinity
Nr1d1 response elements that are also Nr2e3 targets.
As a circadian rhythm regulator, the cellular levels of Nr1d1 are
tightly regulated and are a major determinant of circadian gene
expression program [47,48]. In the retina, both Nr2e3 and Nr1d1
mRNA levels oscillate over a 24-hour period [45]. The retina
contains an intrinsic circadian clock that regulates many aspects of
retinal physiology [49]. More than 2,500 retinal genes have been
identified to have circadian expression, including key photorecep-
tor genes regulated by Nr2e3 and Nr1d1 [50]. Therefore, it is likely
for changes in Nr1d1 concentration to result in altered photore-
ceptor gene expression. We show that delivery of Nr1d1 to the rd7
retina re-regulates two key genes required for proper retinal
function: Opn1sw and Gnat2. Both Opn1sw and Gnat2 function in
the phototransduction process whereby the retina converts light to
an electrical stimulus and as such are essential to vision. We chose
to examine these two genes in rescued eyes because they are
significantly misregulated in rd7 animals and are known direct
targets of NR2E3. Our data strongly suggest that NR1D1-
mediated regulation of key gene networks disrupted by NR2E3
loss contributes to rescue of retinal integrity and function in rd7
animals.
Our study illustrates that modifier genes capable of modulating
a disease state provide viable therapeutic options with broad
applicability. We provide evidence that rescue of disease can be
achieved by delivering a modifier gene rather than replacing the
disease-causing gene. Gene therapy clinical trials have resulted in
tremendous success for treating patients with Leber’s congenital
amaurosis (LCA), an inherited retinal disease [51–55]. These
studies demonstrated the safety and efficacy of gene transfer
through adeno-associated viral (AAV) delivery and have led to
great advancements towards the use of gene therapy in the clinic.
We predict that exploiting modifier genes as candidates for gene
therapy may significantly broaden the therapeutic potential of
AAV to treat retinal diseases and other diseases altered by genetic
modifiers.
In summary, this study demonstrates that modifier genes play
an integral role in disease presentation and as such can be used as
powerful tools for gene therapy that can alter both disease
progression and outcome. Future studies will focus on exploring
the applicability of using Nr1d1 gene delivery for treating Nr2e3-
associated retinal degeneration at advanced stages of disease, as
well as retinal disease with other genetic causes. Specifically, this
therapeutic approach has a powerful mechanism to treat diseases
caused by mutations in different genes that converge on specific
nodes or pathways within a common signaling network and as
such has a much broader impact than single gene replacement
therapy. Further, novel drugs and therapeutics distinct from gene
therapy can be developed to exploit the use of genetic modifiers in
the clinic.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Animal
use and procedures were approved by the University of Nebraska
Medical Center Animal Care and Use Committee and the
Schepens Eye Research Institute Animal Care and Use Commit-
tee (Permit Number: S302-0614) in compliance with the Animal
Welfare Act Regulations. All efforts were made to minimize
animal suffering.
Animal Maintenance
Animals were housed in vivariums at the Schepens Eye
Research Institute and the Nebraska Medical Center. C57BL/6J
and AKR/J mice were obtained from Jackson Laboratories, Bar
Figure 3. GFP expression in P30 rd7 retina electroporated with
GFP.Nr1d1AKR/J at P0. (A) GFP expression (green) is apparent in the
outer nuclear layer (ONL) and inner nuclear layer (INL) of the retina and
co-localizes with the nuclear marker DAPI (blue) (B). INL: inner nuclear
layer, ONL: outer nuclear layer, RPE: retinal pigment epithelium. Scale
bar = 50 mm.
doi:10.1371/journal.pone.0087942.g003
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Harbor, ME. B6.Cg-Nr2e3rd7/rd7 has been previously described
[40]. B6.Cg-Mor7AKR:Nr2e3rd7/rd7 mice were generated by out-
crossing B6.Cg-Nr2e3rd7/rd7 6 AKR/J F2 mice to C57BL/6J,
followed by backcrossing of the F2 progeny to C57BL/6J for six
consecutive generations. Genotyping for the Nr2e3rd7/rd7 mutation
was performed as previously described [38].
Construction of Expression Vectors
cDNA from C57BL/6J or AKR/J mice was used to amplify the
Nr2e3B6, Nr1d1B6 and Nr1d1AKR/J alleles with the following primers:
Nr1d1 (F: TTTTTAAGCTTCATCACAACCTCCAGTTTGT
GTC, R: TTTTTAAGCTTGGCGTCCACCCGGAAGGA-
CAGCA) and Nr2e3 (F: TTTTTAAGCTTGCAAGCAGGC-
TACCCTTAGGACC, R: TTTTTAAGCTTGAACATGTCA
CACAGGAGCTTCT). Amplified sequences spanning the whole
coding sequence were cloned into the pAcGFP1-N1 plasmid from
Clontech. All plasmids were confirmed by direct sequencing using
vector and gene-specific primers.
In vivo Electroporation
Nr1d1 allele specific constructs (designated as GFP.Nr1d1B6 and
GFP.Nr1d1AKR/J) were delivered by subretinal injection into the
right eye of P0.5 rd7 animals using the electroporation method
developed by Matsuda et al. [56]. The Nr2e3 allele from C57B6L/J
(GFP.Nr2e3B6) was electroporated into rd7 animals as a positive
control, while electroporation of empty GFP expression vector or
no injection to the left eye served as a negative control. 1 mg of
naked DNA was injected subretinally, followed by electroporation
immediately with tweezer electrodes at five 80 V pulses of 50 ms
duration, with 950 ms intervals, using a square wave electro-
porator.
Clinical Examination
Animals were examined by indirect ophthalmology at P30 as
previously described [40]. Briefly, pupils of animals were dilated
with 1% Atropine and a Keeler Vantage indirect ophthalmoscope
with a 60-diopter lens was used for fundus examinations.
Quantitative Real Time PCR
Gene expression analysis was performed using quantitative RT-
PCR as previously described [32]. In brief, retinas were dissected
rapidly after eye enucleation and placed in Trizol (Life Technol-
ogies, Carlsbad, CA) for RNA extraction. Eyes were consistently
collected in the early afternoon for each animal in order to
eliminate variability due to circadian expression. Two micrograms
of total RNA was reverse transcribed using Retroscript (Ambion,
Austin, TX). Real-time PCR was performed in technical triplicates
with a minimum of three biological replicates using SYBR Green
PCR master mix (Applied Biosystems, Warrington, UK). The
following primer were used: Nr1d1 (F: CGGCTCAGCGTCA-
TAATGAA, R: GTTGCCTTGCCGTAGACTGTT); Opn1sw (F:
ACCTCTAACAATGGGCTGTGTGA, R: GCTGCCGAAGG-
GTTTACAGA); Gnat2 (F: CCAGCTGGACCGGATTACAG,
R: CAGGTGACTCCCTCGAAGCA) and b-Actin (F: ATGCC-
TCCCCTACCAATCTTC, R: GGATAACGTCCAGGGAAC-
CA). Reactions were quantified using a Roche 480 LightCycler
real time PCR instrument. Relative expression levels were
normalized to the amount of b-Actin expressed and fold change
relative to wild-type C57BL/6J control was calculated using the
delta Ct method. Standard error was calculated to determine
statistical significance.
Statistical Analysis
Statistical analysis for Figures 2 and 4 was performed using the
two-tailed Student’s t test, with significance defined as P,0.05. At
minimum 3 biological replicates were included in the each
experiment.
Electroretinography
Electroretinogram analysis was performed on 7 mice of each
strain (4 month-old), as described previously [40]. Mice were
anesthetized with an intraperitoneal injection of a saline carrier
(10 mg/g body weight) containing ketamine (1 mg/mL) and
xylazine (0.4 mg/mL). Mice were dark adapted for at least six
hours and then anesthetized prior to recording. Dark-adapted
Figure 4. Gene delivery of Nr1d1 suppresses pan-retinal spotting, retinal dysplasia and function in Nr2e3rd7/rd7 mice. (A–F) Fundus
photographs of control and rd7 injected retinas: (A) B6 (uninjected), (B) rd7 (uninjected), (C) GFP injected, (D) GFP.Nr2e3B6 injected, (E) GFP.Nr1d1AKR/J
injected, (F) GFP.Nr1d1B6 injected. (G–J) DAPI staining (blue) shows rescue of defects in retinal morphology 30 days after electroporation into rd7
neonatal retinas. (G) GFP control, (H) Nr2e3B6 injected, (I) GFP control, (J) Nr1d1AKR/J injected. L: left, R: right, GCL: ganglion cell layer, INL: inner nuclear
layer, ONL: outer nuclear layer. Scale bar = 50 mm. (K, L) Representative scotopic (K) and photopic (L) electroretinograms from animals 4 month after
injection with GFP (blue) or GFP.Nr1d1AKR/J (red).
doi:10.1371/journal.pone.0087942.g004
Figure 5. Expression of phototransduction genes Opn1sw and Gnat2 is rescued in rd7 retinas upon Nr1d1 delivery. Quantitative real
time PCR shows that Nr1d1 delivery results in down-regulation of the phototransduction genes Opn1sw and Gnat2 in rd7 retinas (mean 6 SD of
mean, n = 3, p,0.05), to near normal levels.
doi:10.1371/journal.pone.0087942.g005
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responses were recorded to short wavelength (lmax= 470 nm;
Wratten 47A filter) flashes of light over a 4.0 log unit range of
intensities (0.3 log unit steps) up to the maximum allowable by the
photic stimulator. Light-adapted responses were obtained with
white flashes (0.3 step) on the rod-saturating background after
10 min of exposure to the background light to allow complete light
adaptation. Signal processing was performed using EM for
Windows v7.1.2. Signals were sampled every 0.8 ms over a
response window of 200 ms. Responses were averaged for each
stimulus condition with up to 50 records for the weakest signals.
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